Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.76 |
| ▸ | NPC1 | O15118 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | LMNA | P02545 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | CASP3 | P42574 | 1/20 | 0.76 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.76 |
| ▸ | RELA | Q04206 | 1/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17199295 | 0.89 | MEN1 (0.60) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL18169192 | 0.86 | RAB9A (1.00) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL9926874 | 0.82 | RAB9A (0.78) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL29740999 | 0.81 | MAPT (0.63) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL9928341 | 0.76 | MAPT (0.46) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL4013574 | 0.76 | MEN1 (0.48) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL27647508 | 0.75 | MAPT (0.56) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL28194693 | 0.75 | MAPT (0.80) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL3213503 | 0.75 | PTGS2 (0.50) | MAPTNPC1KMT2AMEN1RAB9A | |
| SCHEMBL3226759 | 0.75 | NPC1 (0.55) | MAPTNPC1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | claimed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| EP-2170325-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2010-04-07 | — | — | EP | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| CN-101420952-A | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| WO-2009021747-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009019505-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 4772/4885NPC1 2950/4885KMT2A 3534/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | MAPT 2870/4885NPC1 2697/4885KMT2A 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.